Astrocytes use the MEGF10 receptor to prune synapses in the striatum, a process essential for dopamine-driven motor learning.
The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...